We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
TELIGAN中期结果：Telitacicept降低蛋白尿58.9%，安慰剂组8.8%。了解这种新型双重抑制剂如何改变IgA肾病市场。
